BPI-585771 / Betta Pharma - LARVOL DELTA

BPI-585771: A novel, potent pan-KRAS degrader with potent in vitro and in vivo efficacy in KRAS-driven tumors (AACR 2026) - "Furthermore, BPI-585771 exhibits favorable pharmacokinetic properties and an encouraging preliminary toxicity profile, supporting its advancement into IND-enabling studies and subsequent clinical development. Currently, IND-enabling studies for BPI-585771 are ongoing, and IND submission is expected in Q4 2026."

Late-breaking abstract • Preclinical • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HRAS • KRAS • NRAS